MedTrace Logo

Sebacia Postmarket Study of Real-World Use

NCT03818555 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2020-10-27

No results posted yet for this study

Summary

Postmarket study of Sebacia Microparticles treatment during adoption into clinical use for patients with mild to moderate inflammatory acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

OTHER

Sebacia Microparticles Treatment

Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.

Sponsors & Collaborators

  • Sebacia, Inc.

    lead INDUSTRY

Principal Investigators

  • VP, Clinical & Regulatory Affairs · Sebacia, Inc.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-06-30
Completion
2021-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03818555 on ClinicalTrials.gov